We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aurora Cannabis Inc. (ACB) Flat As Market Sinks: What You Should Know
Read MoreHide Full Article
In the latest trading session, Aurora Cannabis Inc. (ACB - Free Report) closed at $6.25, marking no change from the previous day. This change was narrower than the S&P 500's daily loss of 1.09%. At the same time, the Dow lost 1.23%, and the tech-heavy Nasdaq lost 1.19%.
Heading into today, shares of the company had lost 18.09% over the past month, lagging the Medical sector's loss of 2.37% and the S&P 500's gain of 2.62% in that time.
ACB will be looking to display strength as it nears its next earnings release. In that report, analysts expect ACB to post earnings of -$0.02 per share. This would mark a year-over-year decline of 115.38%. Our most recent consensus estimate is calling for quarterly revenue of $86.93 million, up 485.8% from the year-ago period.
Any recent changes to analyst estimates for ACB should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 47.16% lower within the past month. ACB is currently a Zacks Rank #3 (Hold).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 78, putting it in the top 31% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Aurora Cannabis Inc. (ACB) Flat As Market Sinks: What You Should Know
In the latest trading session, Aurora Cannabis Inc. (ACB - Free Report) closed at $6.25, marking no change from the previous day. This change was narrower than the S&P 500's daily loss of 1.09%. At the same time, the Dow lost 1.23%, and the tech-heavy Nasdaq lost 1.19%.
Heading into today, shares of the company had lost 18.09% over the past month, lagging the Medical sector's loss of 2.37% and the S&P 500's gain of 2.62% in that time.
ACB will be looking to display strength as it nears its next earnings release. In that report, analysts expect ACB to post earnings of -$0.02 per share. This would mark a year-over-year decline of 115.38%. Our most recent consensus estimate is calling for quarterly revenue of $86.93 million, up 485.8% from the year-ago period.
Any recent changes to analyst estimates for ACB should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 47.16% lower within the past month. ACB is currently a Zacks Rank #3 (Hold).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 78, putting it in the top 31% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.